Global Cord Blood Stem Cells Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027

MarketResearch.biz delivers in-depth insights on the global cord blood stem cells market in its upcoming report titled, “Global Cord Blood Stem Cells Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027”. The global cord blood stem cells market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the global cord blood stem cells market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the global cord blood stem cells market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cord blood stem cells market report has been segmented on the basis of storage service, application, and region.

Request Covid - 19 Impact

Three sources for stem cells are bone marrow, peripheral blood, and umbilical cord blood. Blood inside the umbilical cord is called cord blood, and is collected at the time of delivery. Cord blood is a rich source for red blood cells (RBCs), white blood cells (WBCs), platelets, and hematopoietic stem cells, and is extracted and stored in private blood banks with an intention to cure diseases in future if required.

Increasing use of cord blood stem cells in healthcare and pharmaceutical industries is a key factor driving growth of the global cord blood stem cells market. In addition, increasing health concerns toward chronic diseases and blood disorders among the general population, coupled with easy availability, and regenerative nature of stem cells are major factors expected to drive growth of the global cord blood stem cell market over the forecast period.

High costs involved in stem cell storage and use is a key factor restraining growth of the global cord blood stem cell market. Additionally, amount of blood available, mismatches in genetic type, high contamination risk are some major factors hampering growth of the global cord blood stem cells market over forecast period.

However, overcoming challenges with advancements in technology can create opportunities for major players operating in the global cord blood stem cells market.

North America is a dominant player in the global cord blood stem cells market and accounts for largest market share in terms of revenue as compared to that of markets in other regions. This is attributed to well-developed healthcare industry, presence of leading medical diagnostics manufacturers, and increasing number of patients suffering from cancer and blood disorders. Europe accounts for the second-highest revenue share contribution to the global cord blood stem cells market followed by markets in Latin America, Asia Pacific and Middle East & Africa respectively. The market in Asia Pacific is projected to have fastest growth in terms of revenue, owing to increase in number of patients suffering from chronic diseases, and rise in government initiatives for the improvement of healthcare facilities in the region.

Global Cord Blood Stem Cells Market Segmentation:

Global Cord blood stem cell market segmentation by storage service:

• Public cord blood bank
• Private cord blood bank

Global Cord blood stem cell market segmentation by application:

• Blood disease
• Cancer
• Acute leukaemia
• Krabbe diseases
• Other diseases

Global Cord blood stem cell market segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Cord Blood Registry Systems, Inc.
• Viacord Inc.
• China Cord Blood Corporation.
• Cord Blood America, Inc.
• Cryo-Cell International, Inc.
• Cryo-Save AG.
• Cordlife Group Ltd.
• Vita 34 AG.
• Lifecell International Pvt. Ltd.
• Stemcyte Inc.